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RESEARCH ARTICLE Open Access
Methylome analysis of extreme
chemoresponsive patients identifies novel
markers of platinum sensitivity in high-
grade serous ovarian cancer
Tushar Tomar1, Nicolette G. Alkema1, Leroy Schreuder1, Gert Jan Meersma1, Tim de Meyer2, Wim van Criekinge2,
Harry G. Klip1ˆ, Heidi Fiegl3, Els van Nieuwenhuysen4, Ignace Vergote4, Martin Widschwendter5, Ed Schuuring6,
Ate G. J. van der Zee1, Steven de Jong7*† and G. Bea A. Wisman1*†
Abstract
Background: Despite an early response to platinum-based chemotherapy in advanced stage high-grade serous
ovarian cancer (HGSOC), the majority of patients will relapse with drug-resistant disease. Aberrant epigenetic
alterations like DNA methylation are common in HGSOC. Differences in DNA methylation are associated with
chemoresponse in these patients. The objective of this study was to identify and validate novel epigenetic markers
of chemoresponse using genome-wide analysis of DNA methylation in extreme chemoresponsive HGSOC patients.
Methods: Genome-wide next-generation sequencing was performed on methylation-enriched tumor DNA of two
HGSOC patient groups with residual disease, extreme responders (≥18 months progression-free survival (PFS), n = 8)
and non-responders (≤6 months PFS, n = 10) to platinum-based chemotherapy. DNA methylation and expression
data of the same patients were integrated to create a gene list. Genes were validated on an independent cohort of
extreme responders (n = 21) and non-responders (n = 31) using pyrosequencing and qRT-PCR. In silico validation
was performed using publicly available DNA methylation (n = 91) and expression (n = 208) datasets of unselected
advanced stage HGSOC patients. Functional validation of FZD10 on chemosensitivity was carried out in ovarian
cancer cell lines using siRNA-mediated silencing.
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Results: Integrated genome-wide methylome and expression analysis identified 45 significantly differentially
methylated and expressed genes between two chemoresponse groups. Four genes FZD10, FAM83A, MYO18B, and
MKX were successfully validated in an external set of extreme chemoresponsive HGSOC patients. High FZD10
and MKX methylation were related with extreme responders and high FAM83A and MYO18B methylation with
non-responders. In publicly available advanced stage HGSOC datasets, FZD10 and MKX methylation levels were
associated with PFS. High FZD10 methylation was strongly associated with improved PFS in univariate analysis
(hazard ratio (HR) = 0.43; 95% CI, 0.27–0.71; P = 0.001) and multivariate analysis (HR = 0.39; 95% CI, 0.23–0.65; P = 0.003).
Consistently, low FZD10 expression was associated with improved PFS (HR = 1.36; 95% CI, 0.99–1.88; P = 0.058). FZD10
silencing caused significant sensitization towards cisplatin treatment in survival assays and apoptosis assays.
Conclusions: By applying genome-wide integrated methylome analysis on extreme chemoresponsive HGSOC patients,
we identified novel clinically relevant, epigenetically-regulated markers of platinum-sensitivity in HGSOC patients. The
clinical potential of these markers in predictive and therapeutic approaches has to be further validated in prospective
studies.
Keywords: DNA methylation, Integrated methylome analysis, Ovarian cancer, Platinum-based chemotherapy, Extreme
chemoresponders
Background
Epithelial ovarian cancer is the most lethal gynecologic
malignancy [1]. High-grade serous ovarian cancer
(HGSOC), the most abundant histological subtype of
ovarian cancer, is generally diagnosed at an advanced
stage. Standard care of advanced stage patients includes
debulking surgery in combination with platinum-based
chemotherapy in an adjuvant or neoadjuvant setting. Un-
like many other epithelial cancers, HGSOC is initially
hypersensitive to platinum chemotherapy. However, up
to 75% of responding patients relapse with platinum-
resistant disease, resulting in a 5-year survival rate of
below 40% [2, 3]. Furthermore, if a relapse occurs within
6 months after initial treatment (progression-free survival
(PFS) ≤ 6 months), the patient is regarded as ‘platinum re-
sistant’ [4, 5]. Based on clinicopathological parameters, it
is difficult to identify patients who will respond to plat-
inum chemotherapy. As a surrogate indicator for platinum
sensitivity, robust biomarkers associated with very short
PFS might help identify relapse-prone patients. Instead of
undergoing platinum-based chemotherapy, they could be
selected for other novel treatment regimes.
HGSOC differs from other malignancies regarding the
prevalence of somatic gene mutations. Except for the
frequent inactivating mutation of tumor suppressor TP53
(96%) and mutations of the BRCA1/2 (20%) from the
DNA damage repair pathway, mutations in other genes
are rare [6, 7]. However, progression of HGSOC involves
abundant epigenetic alterations, mainly DNA methylation
redistribution, which is characterized by global genomic
hypomethylation and localized hypermethylation [6, 8].
Besides the relative stability of DNA methylation, hyper-
methylation is functionally related to gene expression and
can be easily analyzed in body fluids [9, 10]. Therefore,
DNA methylation can be used as a clinical biomarker.
To date, several studies have been conducted to find
robust DNA methylation biomarkers for ovarian cancer.
Many specific hypermethylated genes have been reported
as potentially useful for diagnosis, prognosis, and/or some-
times for chemoresponse [11–13]. However, most of these
studies included all histological subtypes of ovarian cancer
and were predominantly based on a single candidate gene
approach. Only a few studies have described the identifica-
tion of platinum chemoresponse methylation markers in
HGSOC [14–16]. These studies were based on customized
or commercially available methylation array-based plat-
forms, and were limited by the number of CpG sites or to
genes of specific pathways.
The aim of the present study was to identify putative
methylation markers for chemoresponse in HGSOC.
We took an unbiased genome-wide approach and de-
termined the methylation status of PFS-based extreme
chemoresponder and non-responder HGSOC patients
by performing enrichment of methylated DNA using
the methyl-CpG binding domain of MeCP2 protein
followed by next generation-sequencing (MethylCap-seq).
The differentially methylated profile between extreme
responders and non-responders was integrated with
microarray expression data to identify putative methy-
lation markers for chemoresponse in HGSOC. In
addition, our findings were validated in an independent
patient cohort of extreme responders and non-responders,
which resulted in FZD10, FAM83A, MYO18B, and MKX
as candidate chemoresponse markers. In silico valid-
ation of candidate genes was performed using publicly
available DNA methylation and expression datasets of
unselected advanced stage HGSOC patients to assess
their predictive value. Finally, we functionally validated
FZD10 involvement in platinum sensitivity using in vitro
models.
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Methods
Patient population involved
This retrospective study was conducted in agreement
with the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) criteria for reporting
tumor biomarker prognostic studies [17]. A checklist for
the criteria is provided (Additional file 1).
Set 1 (frozen tissue, University Medical Center Groningen
(UMCG))
The discovery set consisted of prospectively collected
chemo-naïve frozen tumor tissue of 18 patients with
advanced-stage HGSOC operated by a gynecologic on-
cologist from the UMCG (Groningen, the Netherlands)
in the period 1990–2008. All patients were staged ac-
cording to the International Federation of Gynecology
and Obstetrics (FIGO) guidelines. Standard treatment
included debulking surgery followed by adjuvant chemo-
therapy consisting of platinum-based treatment regi-
mens. After chemotherapy, patients were followed for
up to 10 years with gradually increasing intervals. All
the clinicopathological and follow-up data have been
registered in an anonymous, password-protected data-
base, in compliance with Dutch law. All patients gave
informed consent. The responder group consisted of
patients with advanced stage HGSOC, residual disease
after primary surgery (> 2 cm), treated with adjuvant
platinum-based chemotherapy and a PFS of more than
18 months. The non-responder group consisted of pa-
tients with advanced stage HGSOC, residual disease
after primary surgery (> 2 cm), treated with adjuvant
platinum-based chemotherapy and a PFS of less than
6 months. We have p53 and BRCA1/2 status information
for 17 (8 responders and 9 non-responders) out of 18
discovery dataset patients. In this cohort, 16 were p53
mutated, except for one non-responder, and only two
responders showed BRCA2 germline mutation. Detailed
clinicopathological features are described in Additional file
2: Table S1.
Set 2 (mRNA dataset, UMCG)
This previously published gene expression data included
157 consecutive advanced-stage HGSOC patient samples
from UMCG profiled using two-color oligonucleotide
microarrays (35,000 Operon v3.0 probes), manufactured
by The Netherlands Cancer Institute (Amsterdam, the
Netherlands, https://www.nki.nl/topmenu/genomics-core-
facility/, GSE 13876) as described by Crijns et al. [18]. For
expression data integration, we used data from 11 patients
(6 responders and 5 non-responders) who were also in the
discovery set for MethylCap-Seq. Detailed clinicopatho-
logical features are described in Additional file 2: Table S1.
Set 3 (frozen tissue; UMCG + Innsbruck + Leuven)
The external validation cohort consisted of HGSOC pa-
tient tumors from 21 responders and 31 non-responders
obtained from the UMCG, the Medical University of
Innsbruck (Austria), and University Hospital Leuven
(Belgium). All patients were selected based on the same
inclusion criteria as the discovery set (Set 1). Detailed
clinicopathological features are described in Additional
file 2: Table S1.
Sets 4, 5, and 6 (Publicly available external cohort data)
For in silico validation of our findings, we used publicly
available methylation and expression datasets from HGSOC
patients. For methylation Set 4, Infinium 450K methylation
array data of AOCS study group (http://www.aocstudy.org.)
was extracted from the NCBI GEO portal using GEO acces-
sion no. GSE65820 [19] (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE65820) and normalized using a beta-
mixture quantile normalization as described previously [20].
The clinical data of patients was downloaded from the
ICGC data portal (https://dcc.icgc.org/). Methylation probes
for FZD10 (cg23054883), FAM83A (cg24833277), MYO18B
(cg24035545), and MKX (cg14947429), which are related to
same marker regions as identified with MethylCap-seq
(shown in Fig. 2a for FZD10), have been used for univariate
Mantel–Cox log-rank survival analysis to generate Fig. 4a, b
and Additional file 3: Figure S4–S6. For methylation Set 5,
Infinium 27K methylation array data of TCGA study group
along with associated clinical information was extracted
from Genomic Data Commons portal (https://gdc.cancer.-
gov/). Data was beta-mixture quantile normalized and the
FZD10 methylation probe (cg23054883) was used for uni-
variate Mantel–Cox log-rank survival analysis to generate
Additional file 3: Figure S3.
Gene expression data from tumors of Set 6, the cu-
rated ovarian cancer database (Gyorffy et al. database,
http://kmplot.com) [21], with carefully curated clinical
annotations, was extracted in November 2015. We re-
stricted our analysis to primary, high-grade (3), advanced
stage (3 and 4), serous ovarian tumors, residual disease
after surgery or suboptimal debulking, and platinum-
containing therapy with available PFS and overall survival
(OS). For candidate genes, we used the expression data of
FZD10 (Probe ID: 219764_at), FAM83A (Probe ID:
239586_at), MYO18B (Probe ID: 1554579_a_at), andMKX
(Probe ID: 239468_at) to perform univariate Mantel–Cox
log-rank survival analysis and to generate Fig. 4c, d and
Additional file 3: Figure S4–S6.
Detailed clinicopathological features are described in
Additional file 2: Table S1.
DNA extraction and bisulfite modification
Histologic slides of patients were reviewed to confirm
the diagnosis by an experienced gynecologic pathologist.
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Representative frozen blocks of each patient tumor were
retrieved for DNA extraction. Frozen sections of 10 µm
thickness were cut with periodic 4 µm sections prior to
hematoxylin and eosin staining to assess the vital tumor
cell percentage. For some samples, slides were macro-
dissected to obtain more than 85% neoplastic cells. DNA
was isolated using standard salt-chloroform extraction
and isopropanol precipitation. Precipitated DNA was re-
suspended in Tris-EDTA buffer (10 mM Tris; 1 mM
EDTA, pH 8.0). Genomic DNA was amplified with
multiplex PCR according to the BIOMED-2 protocol to
check the DNA’s structural integrity [22]. DNA quantity
was measured using Quant-iT™ PicoGreen® dsDNA Assay
kit according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA, USA). For DNA isolation from cell lines,
the same standard method was followed. Bisulfite conver-
sion was performed using EZ DNA methylationtm Kit
(Zymo Research, Orange, CA, USA) according to the
manufacturer’s protocol using 1 μg of DNA.
MethylCap-seq
MethylCap-seq was performed as described previously
[23, 24]. Briefly, methylated DNA fragments were cap-
tured with methyl binding domains using the MethylCap
kit according to manufacturer’s instructions (Diagenode,
Liège, Belgium). The kit consists of the methyl binding
domain of human MeCP2 as a C-terminal fusion with
glutathione-S-transferase containing an N-terminal His6-
tag. Before capturing, DNA samples (500 ng) were sheared
to a size range of 300–1000 bps using a Bioruptor™
UCD-200 (Diagenode, Liège, Belgium) and fragments
of approximately 300 bp were isolated. Captured DNA
was paired-end-sequenced on the Illumina Genome
Analyzer II platform according to the protocol (Illumina,
San Diego, CA, USA). Results were mapped on the nu-
cleotide sequence using Bowtie software [25], visualized
using BioBix’ H2G2 browser (http://h2g2.ugent.be/bio-
bix.html) and processed using the human reference gen-
ome (NCBI build 37). The paired-end fragments were
unique and located within 400 bp of each other. The
MethylCap-seq data have been deposited in the Gene Ex-
pression Omnibus under accession number GSE97128.
Bisulfite pyrosequencing
Based on the next-generation sequencing results of the
discovery set (Set 1), all pyrosequencing primers were
designed for the selected candidate differentially methyl-
ated regions (DMRs) of 45 genes using PyroMark Assay
Design software (Qiagen, Hilden, Germany). Bisulfite py-
rosequencing was performed as described previously
[26]. Briefly, bisulfite treated DNA was amplified using
PyroMark PCR kit (Qiagen). PCR reaction and cycling
conditions were according to the kit manual. To gener-
ate the PCR product from bisulfite-converted DNA, we
adopted the amplification protocol using a universal
primer approach as described by Collela et al. [27]. The
biotinylated PCR products were captured using 1 μL
streptavidin-coated sepharose high-performance beads
(GE Healthcare, Little Chalfont, UK). The immobilized
products were washed with 70% alcohol, denatured
with PyroMark denaturation solution (Qiagen) and washed
with PyroMark wash buffer (Qiagen). The purified PCR
product was then added to 25 μL PyroMark annealing buf-
fer (Qiagen) containing 0.3 μM sequencing primers for
specific genes (primer sequences are given in Additional
file 4). Finally, pyrosequencing™ reactions were performed
in a PyroMark Q24 MD System (Qiagen) according to the
manufacturer’s instructions using the PyroGold Q24™ Re-
agent Kit (Qiagen). CpG site methylation quantification
was performed using the methylation Software Pyro Q24
2.06 Version (Qiagen).
Cell line culturing
A panel of human ovarian cancer cell lines, A2780, C30,
Cp70, SKOV3, OVCAR3, IGROV1, PEA1, PEA2,
PEO14, and PEO23, was used for in vitro validation and
functional analysis. The source, media, and culture con-
ditions for the cell lines are shown in Additional file 2:
Table S2. All cells were grown at 37 °C in a humidified
atmosphere with 5% CO2 and were detached with 0.05%
trypsin in phosphate-buffered saline (PBS, 0.14 mM
NaCl, 2.7 mM KCl, 6.4 mM Na2HPO4, 1.5 mM KH2PO4,
pH 7.4). Authenticity of all cell lines was verified by
DNA short tandem repeat analysis (Baseclear, Leiden,
The Netherlands) and mycoplasma testing was per-
formed using in-house developed PCR-based method
with specific primers (Invitrogen, NY) against various
mycoplasma species. For global demethylation, cells at
40–50% confluency were treated with demethylating
agent 5-aza-2′-deoxycytidine (DAC) at a final concentra-
tion of 1 μM for 72 h. Due to the low stability of DAC
at 37 °C, the medium was replenished with DAC every
24 h. After 72 h, cells were trypsinized and processed for
RNA and DNA isolation.
Total RNA isolation and quantitative reverse transcriptase
PCR (qRT-PCR)
qRT-PCR was performed as described previously [26].
Total RNA was isolated from frozen tissue blocks and
cell lines using the same procedure as described for
DNA extraction. Total RNA was isolated using RNeasy
mini kit (Qiagen) according to the manufacturer’s in-
structions. RNA was analyzed quantitatively using Nano-
drop (Nanodrop Technologies, Rockland, DE), by using
1 μg of total RNA for cDNA synthesis by a RNase H+
reverse transcriptase using iScript cDNA synthesis kit
(BioRad, Hercules, CA) according to the manufacturer’s
instructions. qRT-PCR was performed in an ABI PRISM
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7900HT Sequence Detector (Applied Biosystems, Foster
City, CA) with the iTaq SYBR Green Supermix with Rox
dye (Biorad). The reactions were analyzed with SDS soft-
ware (Version 2.4, Applied Biosystems). The threshold
cycles (Ct) were calculated and relative gene expression
(ΔCt) was analyzed with GAPDH as the housekeeping
gene (ΔCt = Ctgene – CtGAPDH) (primer sequences given
in Additional file 4). The qRT-PCR primers used are
available upon request. For the final analysis, data was
imported to R to perform clustering and ggplot2 (http://
ggplot2.org/) was used to create heat maps.
siRNA mediated silencing for in vitro experiments
Cells (1–3 × 105) were plated in a 6-well plate and grown
overnight. FZD10 trisilencer-27 siRNAs (Origene
Technologies, Rockville, MD) were used for transient
knock-down using 20 nM of final concentration of
siRNA (sequences given in Additional file 4). Scrambled
and FZD10 targeted siRNAs were transfected using Oligo-
fectamine (Invitrogen, NY) for 4 h with reduced growth
factor serum-free opti-MEM media (Gibco, Life Technolo-
gies, CA). Subsequently, cell line-associated media
(Additional file 2: Table S2) with 30% FCS were added
to make a final FCS concentration of 10% for 48 h. Fol-
lowing 48 h after siRNA transfection, other functional
assays (short- and long-term survival, migration, and
apoptosis) were performed.
Short- and long-term survival assays
Short-term cellular viability was measured with the
micro-culture tetrazolium assay (MTT) as described pre-
viously [28]. Briefly, in a 96-well culture plate, approxi-
mately 7500 SKOV3 cells, 15,000 OVCAR3 cells, 10,000
PEA2 cells, and 12,000 C-30 cells, either control or
siRNA transfected, were seeded in 200 μL culture
medium with or without cisplatin treatment. After 96 h,
20 μL of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT, Sigma-Aldrich, St. Louis, MO,
5 mg/mL in PBS) was added and formazan production
was measured colorimetrically using a Biorad iMark mi-
croplate reader at 520 nm wavelength.
For long-term assay, depending on the concentration
of cisplatin, cells were seeded in 96-well plates at ap-
proximately 2000 cells per well for SKOV3 and 4000
cells per well for OVCAR3. After 8–10 h, indicated
doses of cisplatin were added and allowed to grow for a
set number of days. Finally, cells were fixed and stained
in staining buffer (methanol (50%), acetic acid (20%) and
0.01% Coomassie brilliant blue), washed with water and
dried, after which the plates were scanned. For quantifi-
cation, 200 μL of 10% acetic acid was added to each
well and left on a shaker for 30–60 min. Plates were
read using a Biorad iMark microplate reader at 520 nm
wavelength.
Wound healing assays
For the wound healing assays, cells were seeded in a 6-
well plate at a density of 2 × 105 cells/well and grown
overnight until confluency. A wound was created by
manually scraping the cell monolayer with a 10 μL pip-
ette tip and the medium was aspirated to remove the
detached cells. Cells were then incubated with medium
supplemented only with 10% FCS, and wound closure
was observed within 24 h. Images were acquired with a
Leica camera mounted on an inverted microscope and
were processed using Image J software (NIH, Bethesda,
MD; http://rsb.info.nih.gov/ij/). The distance cells mi-
grated was determined by measuring the wound area at
different time points followed by its correction from the
wound area at time 0 h.
Western blot analysis
Various proteins in ovarian cancer cell lines were detected
by the western blotting method as described previously
[28]. Western blot membranes were probed overnight at
4 °C with primary antibodies (PARP, Cell Signaling Tech-
nology, Danvers, MA, #9532; Cleaved Caspase-3, Cell Sig-
naling Technology, #9661). Afterwards, HRP-conjugated
secondary antibodies (DAKO, Glostrup, Denmark) were
used for detection using Lumi-LightPLUS Western Blotting
Substrate (Roche Diagnostics, Hilden, Germany). Mem-
branes were probed with β-actin antibody (mouse, A5441;
Sigma-Aldrich, St. Louis, MO) to confirm equal loading.
Statistical analysis
MethylCap-seq
All methylation reads data were extracted using BioBix’
H2G2 browser (http://h2g2.ugent.be/biobix.html) for
the broad promoter region (2000 bp upstream and
500 bp downstream of the transcription start site). Read
counts were statistically compared between responder
and non-responder groups using R/Bioconductor [29]
package EdgeR [30], assuming that the data follow a
negative binomial distribution, and ranked on P value.
Subsequently, integration of expression data was also
performed using R-package LIMMA to find differentially
expressed genes [31]. As an additional filter for further
analysis, each candidate DMR had to be methylated (≥ 4
reads) in at least four samples of a specific response group.
Given the fact that putatively relevant loci were selected
based on both differential methylation and expression,
and that several rounds of subsequent independent bio-
logical validation were performed, a relatively permissive
error rate control cut-off (P = 0.05) was used for expres-
sion as well as validation.
Bisulfite pyrosequencing
Methylation percentage results were analyzed using
statistical software IBM SPSS 21 (SPSS Inc., Chicago, IL)
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and a non-parametric statistical test (Mann–Whitney U
test) was performed to find differences between responder
and non-responder groups. P values of less than 0.05 were
assumed to be statistically significant for all tests. To
present data as a heatmap, all methylation percentage data
were imported to Genesis software (Graz University of
technology, genome.tugraz.at/genesis) for clustering and
heatmap visualization.
In silico validation of candidate markers
For prognostic validation of candidate gene methylation,
methylation data of the AOCS and TCGA study groups
was extracted and normalized as mentioned in ‘patient
population involved’ Set 4 and Set 5, respectively. Low
and high methylation cut-offs were based on median
beta value. This resulted in 89 patients for PFS analysis
(proxy for sensitivity to platinum containing chemother-
apy) and 91 patients for OS analysis in AOCS data (Set 4).
For the TCGA cohort (Set 5), we used 91 patients for PFS
analysis and 105 patients for OS analysis. To handle the
missing data, we used the listwise deletion methodology.
For marker expression, data (Set 6) was derived for
analysis using KM plotter [21] in November 2015, in
which we selected only advanced stage (3 and 4) HGSOC
cancer patients with suboptimal debulking surgery, all of
whom had received platinum therapy. This resulted in 200
patients for PFS and 208 patients for OS analysis using
univariate Mantel–Cox log-rank survival analysis with
FZD10 probe (Probe ID: 219764_at), and 100 patients for
PFS and 102 patients for OS analysis with FAM83A (Probe
ID: 239586_at), MYO18B (Probe ID: 1554579_a_at),
and MKX (Probe ID: 239468_at). With an expression
range of probes for different genes, an auto cut-off
value for PFS and OS analysis was used, based on com-
putation of upper and lower quartiles with the default
portal settings [21].
To review the gene expression of FZD10 in other
cancer types, we used the TCGA data from the TCGA
FIREHOSE pipeline (http://gdac.broadinstitute.org/) [32].
To predict FZD10 expression across 41 tumor types, we
used their functional genomic mRNA (FGmRNA) profiles
as described earlier [33, 34]. In this methodology, non-
genetic transcriptional components were used as covari-
ates to correct microarray expression data and the residual
expression signal (i.e., FGmRNA profile) was found to
capture the downstream consequences of genomic al-
terations on gene expression levels [33]. We quantified
the percentage of samples across 41 tumor types with a
significantly increased FGmRNA signal (i.e., a proxy for
underlying gene amplification). For each of the 19,746
tumor samples, FZD10 was marked as significantly
amplified when the FGmRNA signal was above the
97.5th percentile threshold as defined in the non-cancer
samples [33].
In vitro experiments
Statistical significance was calculated by two-sided
Student’s t test between two groups, unless otherwise
mentioned in the figure legends. P values of less than 0.05
were defined as statistically significant for all tests.
Results
Discovery of DMRs in extreme chemoresponse HGSOC
patients
In order to identify the DMRs in relation to platinum-
based chemotherapy, we performed MethylCap-seq on
primary tumor DNA of extreme responder (R = 8, PFS ≥
18 months) and non-responder (NR = 10, PFS ≤ 6 months)
HGSOC patients (Set 1) (Additional file 2: Table S1 and
Fig. 1a). Upon normalization and bioinformatics analysis
(see Methods), 4541 candidate DMRs comprising 3491
genes were identified (P < 0.05). Putative differences be-
tween the extreme responder and non-responder groups
were not due to changes in global methylation, as demon-
strated with the global methylation markers LINE-1 and
ALU-Yb6 (Fig. 1b, c). The putative DMR data (3491 genes)
was integrated with available RNA expression microarray
data from 11 patients (Set 2: 6 responders and 5 non-
responders) out of 18 that were used for MethylCap-seq.
We found 560 genes that were putatively differentially
expressed between the two extreme groups, of which 60
genes were both significantly differentially methylated and
differentially expressed. To make sure that only the most
relevant genes were selected, a DMR had to be methylated
(e.g., four or more reads) in at least four samples in either
the responder or the non-responder group. This resulted
in 49 candidate DMRs comprising 45 genes (Additional
file 5). Figure 1d shows clustering of these selected
markers into two major sub-groups for chemoresponse
with 29 hypomethylated and 20 hypermethylated
DMRs in extreme responders in comparison with non-
responders.
FZD10 was identified as the most differentially
methylated gene between two chemoresponse-related
groups
The 45 candidate genes were verified on the same sam-
ples used for MethylCap-seq by bisulfite pyrosequencing,
as this assay is more quantitative and analyzes individual
CpG sites. Pyrosequencing resulted in nine significantly
differentially methylated genes: FZD10, FAM83A,
MYO18B, MKX, GLI3, TMIG2, TMEM40, NEUROG3, and
HOMER3 (Table 1), of which FZD10 exhibited the clearest
effect. FZD10 was more methylated in extreme chemore-
sponsive patients (significant (P < 0.05) in 5 of 8 CpG sites)
(Fig. 2a, b). In addition, the methylation levels as quantified
by bisulfite pyrosequencing significantly correlated with the
reads of MethylCap-seq (Additional file 3: Figure S1A–D).




Fig. 1 (See legend on next page.)
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The nine selected genes were then validated by bisul-
fite pyrosequencing in an external patient cohort of 21
extreme responders and 31 extreme non-responders (Set
3) with similar clinicopathological characteristics as the
discovery patient cohort (Set 1) (Additional file 2: Table
S1). This resulted in a final list of four candidate genes
(FZD10, FAM83A, MYO18B, and MKX) with at least
one significant CpG site in the external patient cohort
(Table 1). Among these four candidate genes, FZD10
contained the most methylated CpG sites, followed by
FAM83A, MYO18B, and MKX. In agreement with the
verification results, the same four CpGs in FZD10 were
significantly (P < 0.05) highly methylated (Fig. 2b, c) in
the responder group. Likewise, we found significantly
(P < 0.05) higher methylation of MKX in the responder
group, whereas FAM83A and MYO18B showed higher
methylation in the non-responder group.
Candidate markers are epigenetically regulated genes
To validate the impact of DNA methylation on expression
of FZD10, FAM83A, MYO18B, and MKX, we determined
the mRNA expression of available patient RNA samples
for Set 3 using qRT-PCR. We found that the methylation
levels of all four candidate markers were significantly
inversely correlated with gene expression (Fig. 3a and
Additional file 3: Figure S2A). Furthermore, FZD10 gene
expression was significantly lower in the extreme re-
sponder patient group compared to the non-responder
group (Fig. 3b). Subsequently, we obtained similar results
in a panel of 11 ovarian cancer cell lines, showing that
high DNA methylation was related to low gene expression
and vice versa (Fig. 3c, d and Additional file 3: Figure
S2B). Moreover, after treatment with demethylating agent
DAC, the DNA methylation level decreased with subse-
quent upregulation of expression of all four candidate
genes in most cases (Fig. 3c, d and Additional file 3: Figure
S2B). These results indicate that expression of all selected
markers is epigenetically regulated in both ovarian cancer
patients and cell lines.
Predictive and prognostic impact of methylation and
expression of candidate genes
After establishing the relationship between epigenetic
silencing and its expression of validated markers, we
investigated the potential predictive and prognostic value
of marker methylation as well as expression. We used
publicly available methylation and expression datasets
(Sets 4, 5, and 6) with similar clinicopathological charac-
teristics and treatment regimens as our discovery (Set 1)
and validation cohorts (Set 3) without using the extreme
chemoresponse criteria (PFS). After performing Cox
regression analysis, we found that high methylation of
FZD10 was associated with better response to platinum
containing chemotherapy of HGSOC patients (Set 4) as
indicated by PFS (hazard ratio (HR) = 0.43 (0.27–0.71),
P = 0.001) and improved OS (HR = 0.47 (0.28–0.79),
(See figure on previous page.)
Fig. 1 Identification of novel DNA methylation genes by using MethylCap-seq between extreme responder and non-responder HGSOC patients.
a Experimental strategy to evaluate differential DNA methylation regions (DMRs) between extreme chemoresponse patient groups and their
subsequent validation. b and c Bisulfite pyrosequencing for global methylation marker LINE-1 and ALU Yb6 in responder and non-responder
groups showing similar global methylation level. Each bar represents average methylation in % ± SD of either responder (n = 8) or non-responder
(n = 10) at a specific CpG site. d Hierarchical clustering of significant DMRs (49) in the responders (n = 8) and non-responders (n = 10) in the discovery
set (Set 1)
Table 1 Top genes that were verified using bisulfite pyrosequencing
Rank Gene
symbol








expression(Set 1) (Set 3)
1 FZD10 Frizzled-homologue 10 (CD350 antigen) 8 5 4 Yes Inverse
2 FAM83A Family with sequence similarity 83, Member A
(Tumor Antigen BJ-TSA-9)
7 5 4 No Inverse
3 MYO18B Myosin-XVIIIb 3 3 2 No Inverse
4 MKX Homeobox protein Mohawk 4 4 1 Yes Inverse
5 GLI3 GLI Family Zinc Finger 3 6 5 0 Yes Direct
6 TMIGD2 Transmembrane and immunoglobulin
domain-containing 2 (CD28 homologue)
5 4 0 No Direct
7 TMEM40 Transmembrane protein 40 6 6 0 No Direct
8 NEUROG3 Neurogenin-3 16 13 0 Yes Inverse
9 HOMER3 Homer protein homolog 3 7 6 0 No Direct
*P < 0.05
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P = 0.003) (Fig. 4a, b). In addition, we performed similar
prognostic analysis on another independent methylation
dataset from a HGSOC patient cohort (Set 5). Despite the
low average methylation level of the FZD10 methylation
type I probe in Set 5 compared to the type II probe in Set 4
(methylation β-value of 0.022 vs. 0.09, P < 0.001), a trend
was observed for high FZD10 methylation and survival
(PFS: HR = 0.68 (0.39–1.18), P = 0.17; OS: HR = 0.72 (0.44–
1.21), P = 0.21). Moreover, average FZD10 methylation of
extreme responders in this cohort (Set 5) is higher than that
of extreme non-responders (P = 0.059) (Additional file 3:
Figure S3A–C). An opposite relation was found when the
(See figure on previous page.)
Fig. 2 Bisulfite pyrosequencing verification and validation of MethylCap-seq data. a Schematic representation of the genomic region around
the FZD10 gene (chr12: q24.33, 130,647,000–130,650,400) as extracted from the UCSC browser (GRCh37/hg19 [63]; top of figure). The FZD10
MethylCap-Seq region (middle of figure) located 130,647,308–130,647,889 (308–889 bp) downstream of the FZD10 TSS, as retrieved from the
map of the human methylome (BIOBIX, Dept. Mathematical Modelling, Statistics and Bioinformatics, Ghent, University of Ghent, Belgium,
2012, http://www.biobix.be). The reads retrieved by MethylCap-seq analysis comparing 2 normal control leucocytes (black color), 8 responders
(blue color), and 10 non-responders (red color) HGSOC in this region. The known Infinium 450K probes (pink color) and CpG Island (green
color) location as retrieved from the GSE42409 database [64]. The genomic region within the FZD10 as sequenced by bisulfite pyrosequencing
(orange color) (bottom of figure). b Verification of candidate chemoresponse methylation marker FZD10 by bisulfite pyrosequencing in responder (blue
bars, n = 8) and non-responder groups (red bars, n = 10) of discovery set showing significantly higher methylation in responder for FZD10 compared to
non-responder chemoresponse group. c Validation of FZD10 in an independent external cohort of responder (blue bars, n = 21) and non-responders
(red bar, n = 31). Each bar represents average methylation in % ± SD of either responder or non-responder at specific CpG sites. Mann–Whitney U test





Fig. 3 FZD10 is an epigenetically regulated gene by DNA methylation. a Correlation analysis of average methylation as determined by bisulfite
pyrosequencing and relative mRNA level of FZD10 in external cohort patients (n = 32) showed significant inverse correlation between methylation
and their correspondent expression using Pearson correlation testing. b qRT-PCR of FZD10 was performed to determine relative mRNA levels in
responder (n = 10) and non-responder HGSOC patient groups (n = 22). Heatmaps show average methylation percentage (c) and relative mRNA
expression (d) of FZD10 in various ovarian cancer cell lines (n = 11), treated with or without DAC for 72 h (DAC + or –). Most cell lines show
DAC-induced demethylation (from blue to dark red, change in methylation percentage) with subsequent upregulation of mRNA (from black
to green, relative fold expression). Relative gene expression of FZD10 (ΔCt = CtFZD10 – CtGAPDH) for each untreated cell line is mentioned in
front of the heatmap
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predictive and prognostic value of FZD10 gene expression
levels was determined. High FZD10 gene expression (Set 6)
was associated with a worse response and prognosis
(PFS: HR = 1.36 (0.99–1.88), P = 0.058; OS: HR = 1.345
(1.02–2.05), P = 0.037 (Fig. 4c, d)).
In addition, no effect of FAM83A methylation on the
survival of HGSOC patients was observed (Additional
file 3: Figure S4A, B). However, we found that high
FAM83A expression was associated with a better progno-
sis (OS: HR = 0.52 (0.34–0.86), P = 0.01; Additional file 3:
Figure S4D). Furthermore, MYO18B and MKX methyla-
tion were associated with patient survival. High MYO18B
methylation showed a trend towards better response (PFS:
HR = 0.67 (0.43–1.04), P = 0.077) but no association with
overall survival (Additional file 3: Figure S5A, B). Likewise,
high methylation of MKX was associated with better
response and prognosis (PFS: HR = 0.59 (0.38–0.91),
P = 0.018; OS: HR = 0.57 (0.35–0.93), P = 0.024; Additional
file 3: Figure S6A, B).
To investigate whether DNA methylation is an independ-
ent prognostic factor or not, we performed uni- and multi-
variate analyses on age, stage, and all four methylation
markers using the external methylation dataset 4 (n = 91).
We found that neither age nor stage was significantly asso-
ciated with PFS in univariate analysis (Additional file 2:
Table S3). Age was found to be significantly associated
with OS in multivariate analysis (HR = 0.97 (0.94–1.00), P
= 0.040). Notably, in multivariate analysis high FZD10 and
MKX methylation was found to be significantly associated
with better PFS (for FZD10: HR = 0.39 (0.23–0.65), P =
0.003; for MKX: HR = 0.49 (0.31–0.77), P = 0.002) as
well as OS (for FZD10: HR = 0.40 (0.24–0.68), P =
0.001; for MKX: HR = 0.46 (0.28–0.75), P = 0.002;
Additional file 2: Table S3). In conclusion, these re-
sults demonstrate that, among all candidate markers,
only for FZD10 both methylation and expression
have prognostic value for response to platinum-based
chemotherapy in advanced stage HGSOC patients. More-
over, FZD10 methylation also has independent prognostic
value. Hence, we chose FZD10 for further functional val-
idation on ovarian cancer cell lines.
Downregulation of FZD10 enhances cisplatin-induced cell
growth inhibition and apoptosis in ovarian cancer cell lines
FZD10 has been described as a functionally relevant
WNT pathway receptor in several cancer types [35–38].
FZD10 expression has not been previously related to cis-
platin sensitivity. To study the functional role of FZD10
in ovarian cancer, FZD10 gene expression was transi-
ently downregulated in SKOV3 and OVCAR3 cells using
two independent FZD10 targeted siRNAs. We found
70–80% down-regulation of mRNA levels in SKOV3 and
50–60% down-regulation in OVCAR3 for up to 2–4 days
(Additional file 3: Figure S7A). Transient silencing of
a b
c d
Fig. 4 Predictive and prognostic evaluation of FZD10 gene methylation and expression in HGSOC patients. a, b Kaplan–Meier plots showing PFS
(a) and OS (b) for the two patient groups defined based on FZD10 methylation using univariate Mantel–Cox log-rank survival analysis in HGSOC
AOCS cohort (Set 4, n = 89 and n = 91, respectively). Average methylation β-value for ‘Low’ methylation group patients = 0.07 (0.04–0.09) and for
‘High’ methylation group patients = 0.14 (0.09–0.28). c, d Kaplan–Meier plots showing PFS (c) and OS (d) for the two patient clusters based on
FZD10 expression using univariate Mantel–Cox log-rank survival analysis in HGSOC cohorts (Set 6, n = 200 and n = 208, respectively)
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FZD10 did not affect the proliferation rate of cell lines
when compared to scrambled siRNA controls (Additional
file 3: Figure S7B). However, we found significant reduc-
tion (P < 0.001) in the migratory potential of FZD10
siRNA-treated cells as compared with scrambled and
mock controls (Fig. 5a and Additional file 3: Figure S7C).
Short-term survival assays of 4 days showed 2 to 2.5
times greater sensitivity (P < 0.05) to cisplatin in FZD10
siRNA-treated cells (SKOV3, OVCAR3, C-30, and PEA2)
compared to the scrambled siRNA or non-transfected
control counterparts (Fig. 5b, c, Additional file 3: Figure
S7D, E). Furthermore, similar significant cisplatin sensitiz-
ing effects of transient silencing of FZD10 were observed
in long-term survival assays of 10 days in the SKOV3 cell
line (Fig. 5d).
To gain more insight into the cisplatin sensitizing ef-
fect of FZD10 downregulation, we performed apoptosis
staining and analyzed the early apoptotic markers PARP
and caspase 3. A significant increment in apoptosis by
15–40% (P < 0.001) after exposure for 48 h to various
concentrations of cisplatin was observed in FZD10-si-
lenced SKOV3 cells compared to scrambled siRNA and
control cells (Fig. 5e). Apoptosis results were confirmed
by an increase in cleaved PARP and cleaved caspase 3 pro-
tein levels (Fig. 5f). Likewise, downregulation of FZD10 in
OVCAR3 cells resulted in cisplatin sensitization in com-
parison to cisplatin-treated scrambled siRNA and mock
controls (Additional file 3: Figure S7E).
Taken together, these results prove that FZD10 is a de-
terminant of cisplatin sensitivity of ovarian cancer cells.
Discussion
Despite increased understanding of the molecular charac-
teristics of ovarian cancers, no validated clinically relevant
markers for platinum chemoresponse in ovarian cancer
are currently available. In this study, we identified novel
epigenetically-regulated chemoresponse markers for ex-
treme HGSOC platinum responder and non-responder
patients by genome-wide DNA methylation-enriched
sequencing (MethylCap-seq). We discovered that four
genes (FZD10, FAM83A, MYO18B, and MKX) were
differentially methylated and expressed between extreme
responders and non-responders. In silico analysis on pub-
licly available DNA methylation and expression datasets of
unselected advanced stage HGSOC patients showed that
DNA methylation of FZD10 and MKX was independently
prognostic for improved chemoresponse, as reflected by
PFS. In accordance with high FZD10 methylation, low
FZD10 expression was associated with a better chemo-
therapy response and overall survival. Functional analyses
of FZD10 established its clear role in cisplatin sensitivity
and migration of ovarian cancer cells.
Previously, the identification of epigenetic platinum
chemoresponse markers in HGSOC was performed on
customized or commercially available methylation array-
based platforms with a limited number of CpG probes
[14–16]. In the current study, the overall genome-wide
DNA methylation profile information was obtained using
MethylCap-seq. A recent study has shown that MethylCap-
seq technology is a promising unbiased approach for
genome-wide DNA methylation profiling that outperforms
other methylated DNA capturing techniques [39]. Further-
more, MethylCap-seq has comparable coverage of CpG
sites at promoter region and CpG islands to whole-genome
bisulfite sequencing [40]. Moreover, MethylCap-seq has
been shown to be sensitive in various cancer types, includ-
ing head and neck, non-small cell lung cancer and cervical
cancer [24, 41–44]. Thus far, only one study reported a
comprehensive analysis on a large ovarian cancer patient
cohort (n = 101; 75 malignant, 20 benign and 6 normal)
using MethylCap-seq [45]. The DMRs of malignant tumors
were compared to benign or normal samples. However,
platinum chemotherapy response was not included in the
analysis.
By combining the genome-wide methylation and ex-
pression data of HGSOC patients and subsequent valida-
tions, we identified four novel epigenetically regulated
candidate genes (FZD10, FAM83A, MYO18B, and MKX)
that were differentially methylated between extreme re-
sponders and non-responders. In silico analysis of un-
selected advanced stage HGSOC patients showed that
DNA methylation of FZD10 and MKX was independ-
ently associated with a better chemoresponse. Because
FZD10 was the only gene showing both methylation and
expression to have prognostic value for the response to
platinum-based chemotherapy, this study focused further
on FZD10 for functional validation. However, it is possible
that the other genes also play a role in platinum chemore-
sponse in HGSOC. FAM83A, also known as BJ-TSA-9, is
highly expressed in lung cancer [46] and is highly ampli-
fied in many cancer types including breast, ovarian, lung,
liver, prostate, and pancreas [47]. Recently, FAM83A has
been found to be a key mediator of resistance to many
EGFR tyrosine-kinase inhibitors in breast cancer by
causing phosphorylation of c-RAF and PI3K p85, thus
promoting proliferation of and invasion by breast can-
cer cells [48]. MYO18B has been reported to be hyper-
methylated in ovarian cancer and important for
carcinogenesis [11]. MKX (IRXL1) is known for its role
in muscle development [49]; recently, it has been iden-
tified as an epigenetically regulated gene by microRNA
662 in ovarian cancer [50], but its role in ovarian can-
cer is unknown. Interestingly, we previously identified
MKX hypermethylation as an early detection biomarker
for cervical cancer [24]. None of these four genes has
been associated with chemo-resistance or sensitivity in
HGSOC, indicating that all four might be novel che-
moresponse markers for platinum-based chemotherapy.





Fig. 5 FZD10 silencing shows low migratory phenotype in the ovarian cancer cell lines and sensitizes towards cisplatin treatment. a Representative
microphotographs (4× magnification) for wound healing assay on FZD10 siRNA-treated SKOV3 cells for T = 0 and T = 24 h, along with the quantification
of relative wound. Each bar represents % of wound closed ± SD from three independent experiments. ***P < 0.001 for FZD10 siRNA-treated cells in
comparison to the scrambled siRNA (siScrambled), by Student t test. b, c Short-term MTT survival assay on siRNA-treated SKOV3 and OVCAR3 cells and
relative survival in the presence of cisplatin at indicated concentration after 96 h. *P < 0.05; **P < 0.01 for siFZD10-I and ****P < 0.05 for siFZD10-II relative
to expression in siScrambled control, Student t test. IC50 was calculated and mentioned for each group in the inset. d Representative photograph and
quantification of long-term survival assay of SKOV3 cells treated with FZD10 siRNAs. Cells were grown in the absence or presence of cisplatin at
the indicated concentrations for 10 days. e Determination of apoptotic cells in SKOV3 cells treated with siScrambled or FZD10 siRNAs (siFZD10-I or
siFZD10-II). After cisplatin treatment for 48 h, apoptosis induction was analyzed by fluorescence microscopy on acridine orange-stained cells. Each bar
represents % of apoptotic cells ± SD from three or four independent experiments. **P < 0.01, *** P < 0.001 for either siFZD10-I or siFZD10-II with respect
to their siScrambled treated cells. f Protein levels of cleaved PARP and caspase 3 in SKOV3 cells transiently transfected with either FZD10 along with
treatment of cisplatin for 24 h with the indicated concentrations
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FZD10 is a member of the Frizzled family of seven-
transmembrane WNT signaling receptors [51]. FZD10
overexpression has been reported in primary cancers
such as colon, sarcomas, endometrial, gliomas, and ovar-
ian cancer [35–38, 46, 51] (Additional file 3: Figure S8).
FZD10 is assumed to play a role in invasion and metasta-
sis via either the canonical (in colon, endometrial, and
breast cancer) or non-canonical WNT pathway (in sarco-
mas) in a cancer type-dependent manner [36, 38, 52, 53].
In the present study, we showed that downregulation of
FZD10 causes a less migratory phenotype in ovarian
cancer cell lines. Moreover, using a FZD10 silencing ap-
proach, we showed that FZD10 expression is not only
involved in promoting migration, but also causally re-
lated to cisplatin resistance of ovarian cancer cells. In
agreement with these in vitro results, we found that
high FZD10 expressing HGSOC tumors were worse re-
sponders to platinum-based chemotherapy. In a study
on ovarian vascular markers, Buckanovich et al. [54]
showed that low expression of FZD10 in ovarian cancer
is significantly associated (P = 0.001) with better prog-
nosis, which is in line with our findings of significantly
high FZD10 methylation and low FZD10 expression in
the responder patient group in comparison to non-
responders. In addition, our previously published study
[18] on global gene expression analysis of HGSOC pa-
tients (n = 156) also showed that high FZD10 expres-
sion was associated with poor overall survival (HR 1.57,
P = 0.0086). Since FZD10 expression is absent or hardly
detectable in any normal organs except placenta [55]
and highly expressed in ovarian cancer (Additional file 3:
Figure S8), our results indicate that FZD10 is an interest-
ing therapeutic target in ovarian cancer. Furthermore,
considering the expression of FZD10 in other tumor types
(Additional file 3: Figure S8), FZD10 may play a role in
other tumor types like uterine corpus endometrial cancer
and cervical cancer, which are treated with platinum-
based chemotherapy often in combination with radiother-
apy. Notably, FZD10 has been shown to be a therapeutic
target in synovial sarcomas; these sarcomas displayed at-
tenuated growth when targeted by a polyclonal FZD10
antibody [52]. In addition, a radiation-labeled humanized
monoclonal antibody against FZD10 (OTSA101) has been
recently developed, and is currently in phase I clinical
trials for synovial sarcoma [56]. This approach might
also be interesting in the context of chemoresistant
ovarian cancer.
Although HGSOC is known for bearing mutations in a
limited number of genes, aberrant DNA methylation has
been found, which might have an effect on platinum-
based chemotherapy response [19, 45, 57]. In addition to
the four novel epigenetically regulated genes, we also
found other known genes that have been reported for
chemoresponse in ovarian cancer or other cancer types.
For instance, Survivin (BIRC5) was among the top 45
gene list from our analysis and has been reported to be
involved in platinum sensitivity in HGSOC [58]. Another
gene from our analysis, GLI3 (a gene of Hedgehog signal-
ing) has been mentioned as being epigenetically regulated
and linked with platinum response in HGSOC [45]. How-
ever, GLI3 could only be verified with pyrosequencing but
failed during further validation in our study (Table 1). Pre-
vious reports described several hypermethylated genes
that we also found in our initial MethylCap-seq analysis
list (4541 DMRs) (Fig. 1a). For instance, BRCA1 hyperme-
thylation was found to be positively associated with che-
mosensitivity [6, 19, 59]. Furthermore, hypermethylation
of other DNA damage repair pathway-related genes, like
GSTP1, FANCF, and MGMT, has been described to be
positively associated with chemosensitivity in ovarian can-
cer patients [13, 60]. Hypermethylation of genes like ASS1,
MLH1, and MSX1, and WNT pathway-related genes in-
cluding DVL1, NFATC3, and SFRP5 was related to poor
outcome of ovarian cancer patients treated with platinum-
based chemotherapy [13, 14, 61, 62]. These genes were
omitted from the gene list, since we only included genes
that were significantly differentially methylated as well as
expressed between responders and non-responders.
Conclusions
By applying genome-wide integrated methylome analysis
on extreme chemoresponsive HGSOC patients, we iden-
tified novel clinically relevant, epigenetically-regulated
markers of platinum-sensitivity in HGSOC patients.
Resulting candidate genes were successfully validated in
an independent patient cohort. Consequently, we found
FZD10 as a functionally validated novel methylated gene
for platinum-based chemoresponse in HGSOC patients.
The clinical potential of these markers in predictive and
therapeutic approaches has to be further validated in
prospective studies.
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